AMGN vs VRTX
AMGN and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $197.63B | $123.24B |
| P/E (TTM) | 25.5 | 28.8 |
| P/B | 21.50 | 6.37 |
| P/S | 5.4x | 10.3x |
| Dividend yield | 2.59% | — |
| Revenue | $37.22B(TTM) | $12.22B(TTM) |
| Revenue growth (YoY) | 10.0% | 8.9% |
| Net income | $7.80B(TTM) | $4.34B(TTM) |
| Earnings growth (YoY) | 88.5% | 838.1% |
| EPS, diluted | $14.37(TTM) | $16.85(TTM) |
| EBIT margin | 24.7% | 34.8% |
| ROE | 83.9% | 20.4% |
| ROIC | 15.3% | 25.4% |
| 1y total return | +26.0% | +4.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: AMGN frente a VRTX
| Métrica | AMGN | VRTX |
|---|---|---|
| Valor final | $34.7K | $58.6K |
| Retorno total | +246.9% | +486.3% |
| CAGR | +12.8% | +18.7% |
| Volatilidad | 24.7% | 33.2% |
| Sharpe | 0.46 | 0.57 |
| Sortino | 0.67 | 0.83 |
| Caída máxima | -24.9% | -41.6% |
Basado en 2600 días de negociación comunes, 2016-03-15 → 2026-07-17 · tasa libre de riesgo 3.85% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)